Cross Country Healthcare Reports First Quarter 2012 Results
"The start to 2012 has been disappointing, considering the momentum we
had generated in our nurse and allied staffing business in the first ten
months of 2011. I believe the slowing of momentum in this segment
reflected a greater focus by hospitals on temporary nurse staffing usage
during year-end budget discussions that, along with seasonality and a
weak flu season, caused demand for contract nurses to decrease by more
than one-third from mid-November through mid-February. Further
exacerbating this was the loss of a large managed service provider (MSP)
account in September of 2011, just prior to the year-end contraction in
demand. The resulting lower-than-expected revenue in the first quarter
in this segment reduced operating leverage as our overhead was
calibrated to a greater level of staffing activity," said Joseph A.
Boshart, President and Chief Executive Officer of
"More recently we have seen demand increase for our contract nurses by more than 30% from mid-February through the first week of May, although bookings have not yet caught up with this improvement in demand. Moreover, this improvement does not include anticipated positions from one of the nation's leading health care systems which has recently selected us as their MSP provider. To put this into perspective, the projected annual spend for nurse staffing services by this new account represents approximately triple the revenue derived from the MSP account lost last September. We also have several smaller MSP contracts that we anticipate onboarding over the next several months. We expect all of this business to begin ramping up in the third quarter and to be fully in place by the fourth quarter. At the same time, we continue to provide our nurse and allied staffing services during electronic medical record (EMR) implementations — which have contributed to winning some of our recent MSP awards — and are also aggressively pursuing a number of new EMR opportunities," he stated.
"While physician staffing revenue was essentially flat in the first
quarter compared to a year ago, our clinical trial services business saw
top-line growth of 8% and our other human capital segment delivered 9%
revenue growth, driven largely by strong performance from our retained
search business. On a sequential basis, all three of these business
segments saw increases. I remain convinced that the underlying
environment for all of our business segments continues to strengthen and
that our results, driven by our strengthened ability to deliver for our
clients while working more collaboratively with them, will yield
significant value for our shareholders as we move through the coming
quarters," added
Nurse and
For the first quarter of 2012, the nurse and allied staffing business
segment (travel and per diem nurse and allied health staffing) generated
revenue of
Segment staffing volume increased 2% from the prior year quarter and was
essentially flat sequentially. Travel staffing volume increased 3% on a
year-over-year basis, but decreased 1% on a sequential basis while per
diem staffing volume decreased 5% year-over-year, but increased 5%
sequentially. The average revenue per FTE per day for the first quarter
of 2012 was
For the first quarter of 2012, the physician staffing business segment
generated revenue of
Clinical Trial Services
For the first quarter of 2012, the clinical trial services segment
generated revenue of
Other Human Capital Management Services
For the first quarter of 2012, the other human capital management
services business segment (education and training and retained search)
generated revenue of
Debt Outstanding and Credit Facility
During the first quarter of 2012, the Company reduced its debt by
In
Stock Repurchase Program Update
During the first quarter of 2012, the Company repurchased 71,653 shares
of its common stock at an average cost of
Guidance for Second Quarter 2012
The following statements are based on current management expectations. Such statements are forward-looking and actual results may differ materially. These statements do not include the potential impact of any future mergers, acquisitions or other business combinations, any impairment charges or valuation allowances, debt refinancing costs or significant legal proceedings. For the second quarter of 2012, the Company expects:
-
Revenue to be in the
$128 million to $130 million range. - Gross profit margin to be approximately 27.0%.
- Adjusted EBITDA margin to be in the 3.5% to 4.0% range. Adjusted EBITDA, a non-GAAP financial measure, is defined in the accompanying financial statement tables.
-
Earnings per diluted share to be in the range of
$0.01 to $0.03 .
Annual Meeting of Stockholders
At the Company's Annual Meeting of Stockholders held on
Quarterly Conference Call
The Company will hold its quarterly conference call on
Non-GAAP (Generally Accepted Accounting Principles) Financial Measures
This press release and accompanying financial statement tables reference non-GAAP financial measures. Such non-GAAP financial measures are provided as additional information and should not be considered substitutes for, or superior to, financial measures calculated in accordance with U.S. GAAP. Such non-GAAP financial measures are provided for consistency and comparability to prior year results; furthermore, management believes they are useful to investors when evaluating the Company's performance as it excludes certain items that management believes are not indicative of the Company's operating performance. Such non-GAAP financial measures may differ materially from the non-GAAP financial measures used by other companies. The financial statement tables that accompany this press release include a reconciliation of each non-GAAP financial measure to the most directly comparable U.S. GAAP financial measure and a more detailed discussion of each financial measure; as such, the financial statement tables should be read in conjunction with the presentation of these non-GAAP financial measures.
About
In addition to historical information, this press release contains
statements relating to our future results (including certain projections
and business trends) that are "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and are subject to the "safe harbor" created by those
sections. Forward-looking statements consist of statements that are
predictive in nature, depend upon or refer to future events. Words such
as "expects", "anticipates", "intends", "plans", "believes",
"estimates", "suggests", "appears", "seeks", "will" and variations of
such words and similar expressions intended to identify forward-looking
statements. Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results and
performance to be materially different from any future results or
performance expressed or implied by these forward-looking statements.
These factors include, without limitation, the following: our ability to
attract and retain qualified nurses, physicians and other healthcare
personnel, costs and availability of short-term housing for our travel
nurses and physicians, demand for the healthcare services we provide,
both nationally and in the regions in which we operate, the functioning
of our information systems, the effect of existing or future government
regulation and federal and state legislative and enforcement initiatives
on our business, our clients' ability to pay us for our services, our
ability to successfully implement our acquisition and development
strategies, the effect of liabilities and other claims asserted against
us, the effect of competition in the markets we serve, our ability to
successfully defend the Company, its subsidiaries, and its officers and
directors on the merits of any lawsuit or determine its potential
liability, if any, and other factors set forth in Item 1A. "Risk
Factors" in the Company's Annual Report on Form 10-K for the year ended
December 31, 2011, and our other
Although we believe that these statements are based upon reasonable
assumptions, we cannot guarantee future results and readers are
cautioned not to place undue reliance on these forward-looking
statements, which reflect management's opinions only as of the date of
this press release. There can be no assurance that (i) we have correctly
measured or identified all of the factors affecting our business or the
extent of these factors' likely impact, (ii) the available information
with respect to these factors on which such analysis is based is
complete or accurate, (iii) such analysis is correct or (iv) our
strategy, which is based in part on this analysis, will be successful.
The Company undertakes no obligation to update or revise forward-looking
statements. All references to "we," "us," "our," or "Cross Country" in
this press release mean
|
||||||||||||||||||
Consolidated Statements of Operations | ||||||||||||||||||
(Unaudited, amounts in thousands, except per share data) | ||||||||||||||||||
Three Months Ended | ||||||||||||||||||
|
|
December 31, | ||||||||||||||||
2012 | 2011 | 2011 | ||||||||||||||||
Revenue from services | $ | 126,672 | $ | 122,046 | $ | 124,729 | ||||||||||||
Operating expenses: | ||||||||||||||||||
Direct operating expenses | 93,068 | 89,070 | 90,115 | |||||||||||||||
Selling, general and administrative expenses (a) | 31,120 | 28,871 | 29,131 | |||||||||||||||
Bad debt expense | 111 | 238 | 344 | |||||||||||||||
Depreciation | 1,593 | 1,841 | 1,598 | |||||||||||||||
Amortization | 818 | 965 | 818 | |||||||||||||||
Total operating expenses | 126,710 | 120,985 | 122,006 | |||||||||||||||
(Loss) income from operations | (38 | ) | 1,061 | 2,723 | ||||||||||||||
Other expenses (income): | ||||||||||||||||||
Foreign exchange loss (gain) | 71 | 17 | (122 | ) | ||||||||||||||
Interest expense | 629 | 728 | 676 | |||||||||||||||
Other expense (income), net | 36 | (83 | ) | (70 | ) | |||||||||||||
(Loss) income before income taxes | (774 | ) | 399 | 2,239 | ||||||||||||||
Income tax (benefit) expense (a) | (190 | ) | 192 | 1,707 | ||||||||||||||
Net (loss) income | $ | (584 | ) | $ | 207 | $ | 532 | |||||||||||
Net (loss) income per common share: | ||||||||||||||||||
|
$ | (0.02 | ) | $ | 0.01 | $ | 0.02 | |||||||||||
Diluted | $ | (0.02 | ) | $ | 0.01 | $ | 0.02 | |||||||||||
Weighted average common shares outstanding: | ||||||||||||||||||
|
30,766 | 31,103 | 31,108 | |||||||||||||||
Diluted | 30,766 | 31,190 | 31,117 | |||||||||||||||
|
||||||||||||||||||
Reconciliation of Non-GAAP Financial Measures | ||||||||||||||||||
Adjusted EBITDA (b) | ||||||||||||||||||
(Unaudited, amounts in thousands) | ||||||||||||||||||
Three Months Ended | ||||||||||||||||||
|
|
December 31, | ||||||||||||||||
2012 | 2011 | 2011 | ||||||||||||||||
(Loss) income from operations | $ | (38 | ) | $ | 1,061 | $ | 2,723 | |||||||||||
Depreciation | 1,593 | 1,841 | 1,598 | |||||||||||||||
Amortization | 818 | 965 | 818 | |||||||||||||||
Equity compensation | 638 | 644 | 645 | |||||||||||||||
Adjusted EBITDA (b) | $ | 3,011 | $ | 4,511 | $ | 5,784 | ||||||||||||
Adjusted EBITDA Margin (b) | 2.4 | % | 3.7 | % | 4.6 | % | ||||||||||||
|
||||||||||||||||||
Condensed Consolidated Balance Sheets | ||||||||||||||||||
(Unaudited, amounts in thousands) | ||||||||||||||||||
|
December 31, | |||||||||||||||||
2012 | 2011 | |||||||||||||||||
Assets | ||||||||||||||||||
Current assets: | ||||||||||||||||||
Cash and cash equivalents | $ | 8,946 | $ | 10,648 | ||||||||||||||
Short-term cash investments | 1,792 | 1,691 | ||||||||||||||||
Accounts receivable, net | 73,841 | 71,802 | ||||||||||||||||
Deferred tax assets | 11,323 | 10,645 | ||||||||||||||||
Income taxes receivable | 1,868 | 1,879 | ||||||||||||||||
Prepaid expenses | 7,041 | 7,441 | ||||||||||||||||
Other current assets | 638 | 701 | ||||||||||||||||
Total current assets | 105,449 | 104,807 | ||||||||||||||||
Property and equipment, net | 10,746 | 12,018 | ||||||||||||||||
Trademarks, net | 52,099 | 52,053 | ||||||||||||||||
Goodwill, net | 143,550 | 143,344 | ||||||||||||||||
Other identifiable intangible assets, net | 20,407 | 21,195 | ||||||||||||||||
Debt issuance costs, net | 1,038 | 1,199 | ||||||||||||||||
Other long-term assets | 1,362 | 1,294 | ||||||||||||||||
Total assets | $ | 334,651 | $ | 335,910 | ||||||||||||||
Liabilities and Stockholders' Equity | ||||||||||||||||||
Current liabilities: | ||||||||||||||||||
Accounts payable and accrued expenses | $ | 8,628 | $ | 9,018 | ||||||||||||||
Accrued employee compensation and benefits | 16,738 | 16,332 | ||||||||||||||||
Current portion of long-term debt | 22,960 | 16,998 | ||||||||||||||||
Other current liabilities | 5,178 | 4,002 | ||||||||||||||||
Total current liabilities | 53,504 | 46,350 | ||||||||||||||||
Long-term debt | 16,777 | 25,048 | ||||||||||||||||
Non-current deferred tax liabilities | 95 | 58 | ||||||||||||||||
Other long-term liabilities | 14,735 | 15,154 | ||||||||||||||||
Total liabilities | 85,111 | 86,610 | ||||||||||||||||
Commitments and contingencies | ||||||||||||||||||
Stockholders' equity: | ||||||||||||||||||
Common stock | 3 | 3 | ||||||||||||||||
Additional paid-in capital | 243,434 | 243,170 | ||||||||||||||||
Accumulated other comprehensive loss | (2,812 | ) | (3,373 | ) | ||||||||||||||
Retained earnings | 8,915 | 9,500 | ||||||||||||||||
Total stockholders' equity | 249,540 | 249,300 | ||||||||||||||||
Total liabilities and stockholders' equity | $ | 334,651 | $ | 335,910 | ||||||||||||||
|
||||||||||||||||||
Segment Data (c) | ||||||||||||||||||
(Unaudited, amounts in thousands) | ||||||||||||||||||
Three Months Ended | ||||||||||||||||||
|
% of |
|
% of |
|
% of |
|||||||||||||
2012 |
Total |
2011 |
Total |
2011 |
Total |
|||||||||||||
Revenue from services: | ||||||||||||||||||
Nurse and allied staffing | $ | 69,537 | 55% | $ | 66,857 | 55% | $ | 70,287 | 56% | |||||||||
Physician staffing | 29,259 | 23% | 29,436 | 24% | 27,928 | 22% | ||||||||||||
Clinical trial services | 16,872 | 13% | 15,632 | 13% | 15,738 | 13% | ||||||||||||
Other human capital management services | 11,004 | 9% | 10,121 | 8% | 10,776 | 9% | ||||||||||||
$ | 126,672 | 100% | $ | 122,046 | 100% | $ | 124,729 | 100% | ||||||||||
Contribution income (d) | ||||||||||||||||||
Nurse and allied staffing (e) | $ | 3,999 | $ | 5,011 | $ | 5,473 | ||||||||||||
Physician staffing | 2,407 | 2,762 | 2,720 | |||||||||||||||
Clinical trial services | 1,323 | 1,292 | 1,472 | |||||||||||||||
Other human capital management services | 1,110 | 390 | 852 | |||||||||||||||
8,839 | 9,455 | 10,517 | ||||||||||||||||
Unallocated corporate overhead (e) | 6,466 | 5,588 | 5,378 | |||||||||||||||
Depreciation | 1,593 | 1,841 | 1,598 | |||||||||||||||
Amortization | 818 | 965 | 818 | |||||||||||||||
(Loss) income from operations |
$ | (38 | ) | $ | 1,061 | $ | 2,723 | |||||||||||
|
||||||||||||||||||
Other Financial Data | ||||||||||||||||||
(Unaudited) | ||||||||||||||||||
Three Months Ended | ||||||||||||||||||
|
|
December 31, | ||||||||||||||||
2012 | 2011 | 2011 | ||||||||||||||||
Net cash provided by operating activities (in thousands) | $ | 1,401 | $ | 1,373 | $ | 3,666 | ||||||||||||
Nurse and allied staffing statistical data: | ||||||||||||||||||
FTEs (f) | 2,453 | 2,405 | 2,457 | |||||||||||||||
Days worked (g) | 223,223 | 216,450 | 226,044 | |||||||||||||||
Average nurse and allied staffing revenue per FTE per day (h) | $ | 312 | $ | 309 | $ | 311 | ||||||||||||
Physician staffing statistical data: | ||||||||||||||||||
Days filled (i) | 20,617 | 20,668 | 20,200 | |||||||||||||||
Revenue per day filled (j) | $ | 1,419 | $ | 1,424 | $ | 1,383 | ||||||||||||
(a) During the first quarter of 2012 and fourth quarter of 2011,
the Company recorded approximately |
||||||||||||||||||
(b) Adjusted EBITDA, a non-GAAP (Generally Accepted Accounting Principles) financial measure, is defined as income from operations before depreciation, amortization and non-cash equity compensation. Adjusted EBITDA should not be considered a measure of financial performance under GAAP. Management presents Adjusted EBITDA because it believes that Adjusted EBITDA is a useful supplement to income from operations as an indicator of operating performance. Management uses Adjusted EBITDA as one performance measure in its annual cash incentive program for certain members of its management team. In addition, management monitors Adjusted EBITDA for planning purposes, including compliance with its debt covenants. Adjusted EBITDA, as defined, closely matches the operating measure used in the Company's Debt Leverage Ratio and Minimum Fixed Charge Coverage Ratio as defined by its Credit Agreement. Management believes Adjusted EBITDA, as defined, is useful to investors when evaluating the Company's performance as it excludes certain items that management believes are not indicative of the Company's operating performance. Adjusted EBITDA Margin is calculated by dividing Adjusted EBITDA by the Company's consolidated revenue. |
||||||||||||||||||
(c) Segment data provided is in accordance with the Segment Reporting Topic of the FASB ASC. | ||||||||||||||||||
(d) Defined as (loss) income from operations before depreciation, amortization and corporate expenses not specifically identified to a reporting segment. Contribution income is a financial measure used by management when assessing segment performance. |
||||||||||||||||||
(e) Certain first quarter 2011 segment data has been reclassified to conform to current presentation. During 2011, the Company refined its methodology for allocating certain corporate overhead expenses to its nurse and allied staffing segment to more accurately reflect that segment's profitability. |
||||||||||||||||||
(f) FTEs represent the average number of nurse and allied contract staffing personnel on a full-time equivalent basis. | ||||||||||||||||||
(g) Days worked is calculated by multiplying the FTEs by the number of days during the respective period. | ||||||||||||||||||
(h) Average revenue per FTE per day is calculated by dividing the nurse and allied staffing revenue by the number of days worked in the respective periods. Nurse and allied staffing revenue also includes revenue from permanent placement of nurses. |
||||||||||||||||||
(i) Days filled is calculated by dividing the total hours filled during the period by 8 hours. | ||||||||||||||||||
(j) Revenue per day filled is calculated by dividing the applicable revenue generated by the Company's physician staffing segment by days filled for the period presented. | ||||||||||||||||||
Director/Investor
& Corporate Relations
Email: hgoldman@crosscountry.com
Source:
News Provided by Acquire Media